1. Home
  2. BIO vs NUVL Comparison

BIO vs NUVL Comparison

Compare BIO & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIO
  • NUVL
  • Stock Information
  • Founded
  • BIO 1952
  • NUVL 2017
  • Country
  • BIO United States
  • NUVL United States
  • Employees
  • BIO N/A
  • NUVL N/A
  • Industry
  • BIO Biotechnology: Laboratory Analytical Instruments
  • NUVL Biotechnology: Pharmaceutical Preparations
  • Sector
  • BIO Industrials
  • NUVL Health Care
  • Exchange
  • BIO Nasdaq
  • NUVL Nasdaq
  • Market Cap
  • BIO 6.9B
  • NUVL 5.6B
  • IPO Year
  • BIO N/A
  • NUVL 2021
  • Fundamental
  • Price
  • BIO $240.46
  • NUVL $73.48
  • Analyst Decision
  • BIO Strong Buy
  • NUVL Strong Buy
  • Analyst Count
  • BIO 4
  • NUVL 8
  • Target Price
  • BIO $396.50
  • NUVL $115.50
  • AVG Volume (30 Days)
  • BIO 391.3K
  • NUVL 682.1K
  • Earning Date
  • BIO 05-01-2025
  • NUVL 05-08-2025
  • Dividend Yield
  • BIO N/A
  • NUVL N/A
  • EPS Growth
  • BIO N/A
  • NUVL N/A
  • EPS
  • BIO N/A
  • NUVL N/A
  • Revenue
  • BIO $2,566,500,000.00
  • NUVL N/A
  • Revenue This Year
  • BIO $0.88
  • NUVL N/A
  • Revenue Next Year
  • BIO $4.44
  • NUVL N/A
  • P/E Ratio
  • BIO N/A
  • NUVL N/A
  • Revenue Growth
  • BIO N/A
  • NUVL N/A
  • 52 Week Low
  • BIO $215.38
  • NUVL $55.54
  • 52 Week High
  • BIO $387.99
  • NUVL $113.51
  • Technical
  • Relative Strength Index (RSI)
  • BIO 43.98
  • NUVL 54.91
  • Support Level
  • BIO $232.53
  • NUVL $71.60
  • Resistance Level
  • BIO $260.00
  • NUVL $74.28
  • Average True Range (ATR)
  • BIO 12.47
  • NUVL 4.86
  • MACD
  • BIO 1.94
  • NUVL 1.08
  • Stochastic Oscillator
  • BIO 47.20
  • NUVL 95.73

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: